Sarcopenia

Decoding Sarcopenia: Advances in Research and Management: Dive into the evolving landscape of sarcopenia research. From cutting-edge studies on its impact on cancer patients to innovative management strategies, gain insights into combating this muscle-wasting condition.

Improving Hip Fracture Prediction by Using Sarcopenia-Specific Cut-Offs of T-Scores for Osteosarcopenia: A Prospective Cohort Study.

BACKGROUND

Older adults with osteosarcopenia, defined as the coexistence of osteopenia/osteoporosis and sarcopenia, have been associated with an increased risk of fractures compared with those with normal bone mineral density (BMD) and without sarcopenia. However, the conventional definition of osteosarcopenia has...

🗓️ 2026-07-15
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreImproving Hip Fracture Prediction by Using Sarcopenia-Specific Cut-Offs of T-Scores for Osteosarcopenia: A Prospective Cohort Study.

Prognostic performance of Asian Working Group for Sarcopenia 2019 and 2025 sarcopenia definitions in cirrhosis.

BACKGROUND/PURPOSE OF THE STUDY

The Asian Working Group for Sarcopenia (AWGS) updated its criteria in 2025, adding a body mass index (BMI)-adjusted muscle index (ASM/BMI) to the conventional skeletal muscle index (SMI). We aimed to compare the prognostic performances of the...

🗓️ 2026-07-15
📰 Publication: Hepatology International
Read MorePrognostic performance of Asian Working Group for Sarcopenia 2019 and 2025 sarcopenia definitions in cirrhosis.

Sarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank.

OBJECTIVE

To examine whether sarcopenic obesity (SO) is associated with incident type 2 diabetes (T2D) beyond obesity or sarcopenia alone and whether associations differ by sex, age, and transitions in body composition phenotypes over time.

RESEARCH DESIGN AND METHODS

We studied 479,607 diabetes-free...

🗓️ 2026-07-13
📰 Publication: Diabetes Care
Read MoreSarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank.

Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition.

Sarcopenia is the age-related loss of muscle strength and size that leads to mobility limitations and loss of independence in older adults. The underlying cellular mechanisms remain unclear, and treatments are limited. As the critical interface between the nervous system...

🗓️ 2026-07-09
📰 Publication: Journal Of Clinical Investigation
Read MoreNeuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition.

Assessing the relationships between frailty, sarcopenia and Alzheimer's disease biomarkers: a scoping review.

INTRODUCTION

While both frailty and sarcopenia have been linked with the Alzheimer's disease (AD) clinical phenotype, their association with AD pathophysiology is unclear. This review aimed to identify current evidence of relationships between frailty, sarcopenia and AD biomarkers.

METHODS

Four databases (Ovid MEDLINE,...

🗓️ 2026-07-08
📰 Publication: Ageing Research Reviews
Read MoreAssessing the relationships between frailty, sarcopenia and Alzheimer's disease biomarkers: a scoping review.

Prognostic performance of Asian Working Group for Sarcopenia 2025 Constructs for activities of daily living at discharge after stroke: a head-to-head validation.

PURPOSE

To compare the prognostic performance of the Asian Working Group for Sarcopenia (AWGS) 2025 diagnostic constructs-specifically height- versus body mass index (BMI)-indexed muscle mass-for discriminating functional outcomes in patients with stroke.

METHODS

From a cohort of 1246 consecutive post-acute stroke admissions, we...

🗓️ 2026-07-07
📰 Publication: European Geriatric Medicine
Read MorePrognostic performance of Asian Working Group for Sarcopenia 2025 Constructs for activities of daily living at discharge after stroke: a head-to-head validation.

Differences in Circulating Inflammatory Markers in Older Adults With and Without Sarcopenia: A Systematic Review and Meta-Analysis.

OBJECTIVES

In this systematic review and meta-analysis, mean differences among high-sensitivity C-reactive protein (CRP), CRP, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), the most common markers used in clinical practice, between older adults with and without sarcopenia based on established consensus...

🗓️ 2026-07-04
📰 Publication: Journal Of The American Medical Directors Association
Read MoreDifferences in Circulating Inflammatory Markers in Older Adults With and Without Sarcopenia: A Systematic Review and Meta-Analysis.

Bidirectional Relationship and Shared Mechanisms Between Sarcopenia and Osteoporosis: An Observational Study Integrating Genomic, Proteomic, and Metabolomic Data.

With global population aging, sarcopenia and osteoporosis have become critical public health challenges. Muscles and bones are closely interconnected anatomically and functionally, but the biological mechanisms connecting sarcopenia and osteoporosis have not yet been fully elucidated. This study systematically investigated...

🗓️ 2026-07-01
📰 Publication: Aging Cell
Read MoreBidirectional Relationship and Shared Mechanisms Between Sarcopenia and Osteoporosis: An Observational Study Integrating Genomic, Proteomic, and Metabolomic Data.

Brain-Derived Neurotrophic Factor, Sarcopenia and Digital Gait Characteristics in Older Adults: Insights Into the Brain-Muscle Axis.

BACKGROUND

Brain-derived neurotrophic factor (BDNF) is a core biomarker involved in the brain-muscle axis. This study aimed to investigate the associations of plasma BDNF with sarcopenia and multidimensional gait characteristics in older adults.

METHODS

We enrolled 646 adults aged 60 years and older (mean...

🗓️ 2026-06-30
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreBrain-Derived Neurotrophic Factor, Sarcopenia and Digital Gait Characteristics in Older Adults: Insights Into the Brain-Muscle Axis.

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

BACKGROUND

Cancer-related sarcopenia is associated with poor clinical outcomes but remains difficult to define and quantify in routine oncology practice. Current assessments rely on imaging and functional scales that are time-consuming and provide limited biological insight. We aimed to identify a...

🗓️ 2026-06-30
📰 Publication: Molecular Cancer
Read MoreA plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

Cellular senescence in musculoskeletal diseases: biological mechanisms and clinical implications.

Cellular senescence is a persistent state of irreversible growth arrest that occurs when cells encounter various stress signals. It is marked by elevated expression of cell cycle inhibitors, dysregulated gene transcription, and secretion of the senescence-associated secretory phenotype (SASP). These...

🗓️ 2026-06-29
📰 Publication: Theranostics
Read MoreCellular senescence in musculoskeletal diseases: biological mechanisms and clinical implications.

Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review.

BACKGROUND

Pancreatic ductal adenocarcinoma (PDAC) is characterised by a high prevalence of severe muscle wasting (sarcopenia) and fatty muscle infiltration (myosteatosis), yet chemotherapy dosing still relies on body surface area (BSA), a metric that does not reflect individual patients' lean body...

🗓️ 2026-06-27
📰 Publication: Cancer Treatment Reviews
Read MoreBeyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review.

Icariin ameliorates sarcopenia via activation of the estrogen receptor α/fatty acid transport protein 1 pathway.

BACKGROUND

Sarcopenia is a prevalent disorder among postmenopausal women, representing a debilitating condition with limited treatment options. Icariin (ICA), a prenylated flavonol glycoside, is commonly used in conditions associated with estrogen deficiency; however, its efficacy and mechanism in postmenopausal sarcopenia remain...

🗓️ 2026-06-25
📰 Publication: Phytomedicine
Read MoreIcariin ameliorates sarcopenia via activation of the estrogen receptor α/fatty acid transport protein 1 pathway.

Associations of length of stay with sarcopenia parameters in geriatric patients: age and sex differences in the oldest old.

BACKGROUND

Hospital-associated deconditioning is a contributor to secondary sarcopenia, which may be driven by prolonged hospital length of stay (LoS). This study investigated the bidirectional association of LoS and sarcopenia indices (lean soft tissue, muscle strength, physical function) in older inpatients,...

🗓️ 2026-06-25
📰 Publication: Aging Clinical And Experimental Research
Read MoreAssociations of length of stay with sarcopenia parameters in geriatric patients: age and sex differences in the oldest old.

SARCOPENIA DEFINITION

Sarcopenia is a condition which focuses on muscle loss. Loss of muscle mass and function, especially muscle strength and gait speed, associated with aging occurs in sarcopenia. Sarcopenia, cachexia, and malnutrition are considered as the main causes of muscle wasting and affect millions of elderly people and patients. Moreover, muscle atrophy can develop independently from diseases and age through disuse of the muscles. For a better classification and common language in medical science for ‘muscle wasting disease’ there is a proposal to combine the concepts of muscle wasting, sarcopenia, frailty, and cachexia by disease aetiology and disease progression. Patients with muscle atrophy show decreased muscle strength and therefore reduced quality of life, which is caused by a lower activity and increased exercise intolerance.

Despite a large number of studies, the understanding of the development of muscle wasting and the involved pathways remains very limited and more research is needed. Although many researchers and pharmaceutical companies have tried to find therapies for muscle atrophy, including cachexia and sarcopenia, no solution has been established until now.

REFERENCES

Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med 2011;27:337–339.

Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, Kalantar-Zadeh K. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014;5:1–3

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!